Cardiovascular pharmacology of SCH 59761, a highly potent, non‐selective, adenosine receptor agonist

@article{Casati1996CardiovascularPO,
  title={Cardiovascular pharmacology of SCH 59761, a highly potent, non‐selective, adenosine receptor agonist},
  author={C. Casati and G. Lozza and A. Conti and E. Ongini and A. Monopoli},
  journal={Drug Development Research},
  year={1996},
  volume={39}
}
  • C. Casati, G. Lozza, +2 authors A. Monopoli
  • Published 1996
  • Medicine
  • Drug Development Research
  • The therapeutic application of selective adenosine agonists is hampered by the difficulty of separating desirable actions from side effects. A non‐selective agent, combining A1 and A2A properties, might have advantages in this regard. In the present study, the pharmacological properties of N‐ethyl‐1′‐deoxy‐1′{6‐amino‐2‐[1‐(3‐hydroxy‐3‐phenyl)‐propynyl]‐9H‐purin‐9‐yl} ‐β‐D‐ribofuran‐5′‐uronamide (SCH 59761), a potent, non‐selective adenosine agonist, were evaluated. The drug SCH 59761 showed… CONTINUE READING

    References

    SHOWING 1-10 OF 35 REFERENCES
    In vitro and in vivo characterization of an A1-selective adenosine agonist, RG14202.
    • 25
    [3H]CGS 21680, a selective A2 adenosine receptor agonist directly labels A2 receptors in rat brain.
    • 501
    Cardiovascular and antilipolytic effects of the adenosine agonist GR79236.
    • 26
    Effects of adenosine derivatives on human and rabbit platelet aggregation
    • 41